Professor of Medicine, UCLA-David Geffen School of Medicine
Infectious Disease
Dr. Eric S. Daar, MD
|
|
Give Review
Eric S. Daar, MD is an expert in the field of Infectious Disease. He researched medicine at Georgetown University School of Medicine. Georgetown University School of Medicine is ranked 49 in research and 84 in primary care medicine He received awards:"America's Top Doctors", "Top Doctors:LA Area", "Top Doctors:Southern California", "Super Doctor" and "Whos Who in Medicine and Healthcare". Doctor Eric S. Daar, MD has written publications. He has 80 publications published with PubMed. The lastest publication is: 'Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men.' Eric S. Daar, MD accepts all Medicare patients.
Publications
- Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission Behavior Among HIV Infected Men Who have Sex with Men.
- A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.
- Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
- Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights f...
- Plasma and cerebrospinal fluid biomarkers predict cerebral injury in HIV-infected individuals on stable combination antiretroviral therapy.
- Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine ve...
- Antiretroviral Therapy: Treatment-experienced Individuals.
- Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
- Ineffectual Targeting of HIV-1 Nef by Cytotoxic T Lymphocytes in Acute Infection Results in No Functional Impairment or Viremia Reduction.
- Impaired Nef function is associated with early control of HIV-1 viremia.
- HIV-1 gag Genetic Variation in a Single Acutely Infected Participant Defined by High-Resolution Deep Sequencing.
- Antiretroviral Therapy and Efficacy after Virologic Failure on First-line Boosted Protease Inhibitor Regimens.
- Cytomegalovirus Replication in Semen is Associated with Higher Levels of Proviral HIV DNA and CD4+ T cell Activation during Antiretroviral Treatment.
- Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.
- Impact of randomized antiretroviral therapy initiation on glucose metabolism: AIDS clinical trials group study A5224s.
- Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
- Factors associated with high transmission risk and detectable plasma HIV RNA in HIV-infected MSM on ART.
- Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine.
- Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a substudy o...
- Modeling the Impact of Post-Diagnosis Behavior Change on HIV Prevalence in Southern California Men Who Have Sex with Men (MSM).
- Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.
- Limited Nucleotide Changes in the Rev Response Element During HIV-1 Infection Alter Overall Rev-RRE Activity and Rev Multimerization.
- Virologic Correlates of Anti-CMV IgG Levels in HIV-1 Infected Men.
- Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.
- Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1 infected men who have sex with men.
- Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
- Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS ...
- Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.
- HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status.
- Role of GB Virus C in Human Immunodeficiency Virus Type-1- and Hepatitis C Virus-infected Hemophiliac Children and Adolescents.
- Barriers and Unmet Need for Supportive Services for HIV Patients in Care in Los Angeles County, California.
- Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s.
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With ...
- Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.
- Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.
- Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types.
- Impaired replication capacity of acute/early viruses in persons who become HIV controllers.
- Newer antiretroviral agents and how to use them.
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
- Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies.
- Emerging resistance profiles of newly approved antiretroviral drugs.
- Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men.
- Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination.
- Clinical presentation and diagnosis of primary HIV-1 infection.
- Incorporating novel virologic tests into clinical practice.
- Unprotected anal intercourse and substance use before and after HIV diagnosis among recently HIV-infected men who have sex with men.
- Hepatitis C virus and death risk in hemodialysis patients.
- New approaches and resolve may define the future of the global HIV pandemic.
- Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners.
- Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
- Novel antiretroviral agents in HIV therapy.
- Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection.
- Transmission behaviors of recently HIV-infected men who have sex with men.
- Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access.
- Diagnostic discordance for hepatitis C virus infection in hemodialysis patients.
- HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load.
- Primary human immunodeficiency virus type 1 infection.
- Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.
- Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance.
- Strategies for initiating combination antiretroviral therapy.
- Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment.
- Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains.
- Incidence of HIV superinfection following primary infection.
- What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.
- What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1.
- Antiretroviral rounds. Putting resistance to work.
- Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes.
- Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.
- Potency and durability of antiretroviral therapy.
- Antiretroviral resistance in clinical practice.
- Antiretroviral rounds. The when, why and how of switching.
- Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.
- Improving adherence to antiretroviral therapy.
- Treatment of primary HIV infection.
- Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection.
- Antiretroviral-drug resistance among patients recently infected with HIV.
- Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine.
- Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
- Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment.
Schools
Georgetown University
Cedars Sinai Med Center
Doctors Specialties
- Internal Medicine
- Infectious Disease
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- Top Doctors:Southern California
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
Cedars-Sinai Medical Center -
Georgetown University School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Harbor-UCLA Medical Center
Drug Facts
| NPI NUMBER | 1336119676 | |
| NPPES Provider LastName | DAAR | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 905022047 | |
| NPPES Provider State | CA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 206.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 5.83 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336119676 |
| Last Name Of The Provider | DAAR |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
|
Dr. Philip W. Chung, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Addie B. Spier, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Karen S. Black, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric Yan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace T. Kiet, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meena E. Lagnese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Loren G. Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angel A. Wang, MD
This Doctor is OpenDoctor Recommended.
|